ERBB2 and breast carcinoma: T-DM1 is an antibody–drug conjugate combining trastuzumab with a cytotoxic agent and is approved for HER2-positive metastatic or unresectable breast cancer based on studies such as the EMILIA and TH3RESA trials [4,5].